Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia

PHASE2TerminatedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions
Hypercholesterolemia
Interventions
DRUG

Lapaquistat acetate

Lapaquistat acetate 100 mg, tablets, orally, once daily in the morning and Lapaquistat acetate placebo-matching tablets, orally, once daily in the evening for up to six weeks.

DRUG

Lapaquistat acetate

Lapaquistat acetate placebo-matching tablets, orally, once daily in the morning and Lapaquistat acetate 100 mg, tablets, orally, once daily in the evening for up to six weeks.

DRUG

Lapaquistat acetate

Lapaquistat acetate 50 mg, tablets, orally, once daily in the morning and Lapaquistat acetate 50 mg, tablets, orally, once daily in the evening for up to six weeks.

DRUG

Placebo

Lapaquistat acetate placebo-matching tablets, orally, once daily in the morning and Lapaquistat acetate placebo-matching tablets, orally, once daily in the evening for up to six weeks.

Trial Locations (22)

Unknown

Long Beach

Sacramento

San Diego

Hollywood

Jacksonville

New Port Richey

Chicago

Wichita

Louisville

Margate City

Charlotte

Raleigh

Statesville

Wilmington

Winston-Salem

Medford

Perkasie

Sellerville

Bristol

Norfolk

Richmond

Madison

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY